Acasunlimab

Acasunlimab (GEN1046) is a bispecific antibody developed by Genmab. Its target is PD-L1 (the sponsor names PD-L1 x 4-1BB (CD137)). The sponsor states: Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy. ClinicalTrials.gov describes the intervention as: Acasunlimab will be administered intravenously (IV). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)), in non-small-cell lung cancer. The largest, NCT06635824, plans to enrol 191 participants (actual) with primary completion expected 2027-07-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.